AACR 2023 | HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in advanced solid tumors

Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, provides an overview of HST-1011, a novel, potent, selective, orally bioavailable allosteric small molecule CBL-B inhibitor that has been shown to robustly increase anti-tumor immunity in vitro and in vivo, including in model systems where other immune checkpoint inhibitors (ICIs) have minimal effect. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.